Suppr超能文献

用于生物标志物检测的表面等离子体激元酶联免疫吸附测定:机制、功能化策略及新兴模式综述

Plasmonic ELISA for Biomarker Detection: A Review of Mechanisms, Functionalization Strategies, and Emerging Modalities.

作者信息

Shoukat Chaudhary Ammar, Tariq Maryam, Aqib Raja Muhammad, Tajwar Muhammad Ali, Iqbal Rashid

机构信息

Institute for Advanced Study, Shenzhen University, Shenzhen 518060, P. R. China.

College of Resources and Environment, University of Chinese Academy of Sciences, Beijing 100049, China.

出版信息

ACS Appl Bio Mater. 2025 Jul 21;8(7):5512-5531. doi: 10.1021/acsabm.5c00738. Epub 2025 Jun 17.

Abstract

Plasmonic enzyme-linked immunosorbent assay (ELISA) effectively integrates noble metal nanostructures with traditional immunoassays, facilitating rapid, ultrasensitive, and multiplexed biomarker detection. By leveraging localized surface plasmon resonance modulations instigated by biocatalytic reactions and analyte binding, these assays achieve signal amplification through growth, etching, and aggregation mechanisms. Such methodologies significantly enhance detection limits by factors ranging from 10- to over 1000-fold, attaining sensitivity at the subpicogram per milliliter level. Robust surface functionalization methods, including electrostatic adsorption, covalent coupling, and affinity binding, ensure stable immobilization of antibodies while preserving the activity of the nanozymes. Incorporating advanced two-dimensional nanomaterials, such as graphene derivatives and MXenes, further augments the sensitivity (up to ∼200-fold), assay stability, and potential for miniaturization. Emerging modalities, including electrochemical techniques, microfluidics, photothermal methods, surface-enhanced infrared absorption (SEIRA), surface-enhanced Raman scattering, and CRISPR-enabled ELISA, extend the analytical versatility, multiplexing capabilities, and operational speed. Clinical trials, alongside real-world studies, substantiate the efficacy of plasmonic ELISA platforms in early cancer detection, diagnostic evaluation of infectious diseases, and monitoring cardiovascular biomarkers, demonstrating performance comparable to or exceeding that of traditional methodologies. Despite significant advancements, challenges persist with regard to assay standardization, multiplex integration, and large-scale manufacturing. This review presents a comprehensive overview of recent developments, identifies critical knowledge gaps, and outlines future perspectives to expedite the clinical translation of plasmonic ELISA technologies for precision medicine and global health applications.

摘要

等离子体酶联免疫吸附测定(ELISA)有效地将贵金属纳米结构与传统免疫测定相结合,有助于快速、超灵敏和多重生物标志物检测。通过利用生物催化反应和分析物结合引发的局部表面等离子体共振调制,这些测定通过生长、蚀刻和聚集机制实现信号放大。这些方法显著提高了检测限,提高倍数从10倍到超过1000倍不等,达到了每毫升亚皮克级的灵敏度。强大的表面功能化方法,包括静电吸附、共价偶联和亲和结合,确保抗体的稳定固定,同时保留纳米酶的活性。结合先进的二维纳米材料,如石墨烯衍生物和MXenes,进一步提高了灵敏度(高达约200倍)、测定稳定性和小型化潜力。新兴的模式,包括电化学技术、微流体技术、光热方法、表面增强红外吸收(SEIRA)、表面增强拉曼散射和基于CRISPR的ELISA,扩展了分析的多功能性、多重检测能力和操作速度。临床试验以及实际研究证实了等离子体ELISA平台在早期癌症检测、传染病诊断评估和心血管生物标志物监测方面的有效性,其表现与传统方法相当或超过传统方法。尽管取得了重大进展,但在测定标准化、多重整合和大规模制造方面仍存在挑战。本综述全面概述了近期的发展,确定了关键的知识差距,并概述了未来的前景,以加速等离子体ELISA技术在精准医学和全球健康应用中的临床转化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验